Memorial Sloan Kettering Cancer Center (MSKCC)In September 2014, SELLAS announced an exclusive global collaboration and exclusive license agreement with Memorial Sloan Kettering Cancer Center (MSKCC) for the development, marketing and commercialization of MSKCC’s proprietary WT1 cancer immunotherapy.

WT1 is over-expressed in many human cancers, including most blood cancers and many solid tumors, including mesothelioma, and cancers of the ovary, lung, gastrointestinal tract, breast, and prostate. The National Cancer Institute recently ranked WT1 as the top target for cancer immunotherapy. MSKCC researchers have already shown the potential of this immunotherapy to safely immunize patients against the WT1 antigen in several clinical trials. SELLAS will now further develop the drug in other, larger studies.


CordenPharma CordenPharma International is a full-service partner in the contract development & manufacturing of APIs, drug products, and associated packaging services. Through a network of fully-inspected cGMP facilities across Europe and the US organized under five technology platforms – Peptides, Lipids & Carbohydrates, Injectables, Highly Potent & Oncology, Small Molecules, Antibiotics - CordenPharma experts translate complex ideas at any stage of development into high-value products.


PolyPeptide Group The PolyPeptide Group is a contract manufacturing organization for peptides and peptide related molecules. The group is one of the world’s largest independent contract manufacturers of therapeutic peptides for the cosmetic, pharmaceutical and veterinary markets employing more than 450 people in six manufacturing sites located in France, India, Scandinavia and the USA. The company manufactures over one third of all approved peptide drug substances (22 of 62 approved products worldwide) accounting for over 25% of the sales of outsourced peptide therapeutics worldwide.


Advaxis SELLAS has a license with Advaxis to develop a novel cancer immunotherapy agent using Advaxis’ Lm-based antigen delivery technology with SELLAS’ patented WT1 targeted heteroclitic peptide antigen mixture (galinpepimut-S).

For enquiries related to partnering opportunities, please email: